All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.

The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your Lymphoma Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
2017-04-07T16:30:17.000Z

AACR 2017 | Poster 2033/5 – Testing the combined effects of low dose olaparib plus ibrutinib on Mantle Cell Lymphoma cytotoxicity

Apr 7, 2017
Share:

Bookmark this article

On Monday 3rd April during this year’s American Association for Cancer Research (AACR) annual meeting, a poster (2033 / 5) by Adam D. Curtis, from the Eastern Maine Medical Center, Brewer, ME, et al. titled “Testing the combined effects of low dose olaparib plus ibrutinib on MCL cytotoxicity” was presented.

The group aimed to potentially improve ibrutinib therapy for MCL by combining it with olaparib, a DNA damage response inhibitor, and testing the combination in MCL cells in vitro.

Key Highlights:

  • Ibrutinib monotherapy is cytotoxic to MCL cell lines but only at high doses (>25μM)
  • MCL growth is more sensitive to olaparib that ibrutinib
  • Olaparib monotherapy treatment is cytotoxic to MCL cell lines at lower concentrations (10μM) than ibrutinib
  • Low doses of ibrutinib combined with olaparib inhibited MCL cell growth more than either drug alone at concentrations <EC50
  • The ibrutinib-olaparib combination increases apoptosis and MCL cell death

The poster was concluded by hypothesizing that ibrutinib combined with olaparib potentially could improve response rate and duration in patients with MCL, as well as reducing adverse events.

  1. Curtis A.D. et al. Testing the combined effects of low dose olaparib plus ibrutinib on MCL cytotoxicity [Poster]. In: Proceedings of the 107th Annual Meeting of the American Association for Cancer Research; 2017 Apr 1-5; Washington, DC. Philadelphia (PA): AACR; 2017. Poster nr [2033 / 5].

Understanding your specialty helps us to deliver the most relevant and engaging content.

Please spare a moment to share yours.

Please select or type your specialty

  Thank you

Newsletter

Subscribe to get the best content related to lymphoma & CLL delivered to your inbox